Stockpolly
Search
JBIO · NASDAQ · Biotechnology

Jade Biosciences (JBIO)

Developing antibody therapies for IgA nephropathy and systemic autoimmune diseases.

$21.43
At close+0.41 (+1.95%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
2122252615632827354359
Research & development1718202114202322293650
445515355679
Selling & marketing000000000000
General & administrative000010055600
Operating income−21−22−25−26−15−6−3−28−27−35−43−59
2211−111−42333
Interest income221101122333
Other non-operating income−2−2−1−11−1−14−2−3−30
Income before tax−20−20−23−25−16−5−3−32−25−32−40−56
Income tax expense000000000000
Net income from continuing operations−20−20−23−25−16−5−3−32−25−32−40−56
Net income−20−20−23−25−16−5−3−32−25−32−40−56
EPS, basic−$24.77−$25.80−$29.20−$30.15−$5.16−$6.56−$3.04−$1.13−$0.64−$0.65−$0.70−$0.76
EPS, diluted−$24.77−$25.80−$29.20−$30.15−$5.16−$6.56−$3.04−$1.13−$0.64−$0.65−$0.70−$0.76
Weighted average shares, basic11113112840495861
Weighted average shares, diluted11113112840495861
EBITDA−20−20−23−25−16−5−3−32−25−32−40−59
Depreciation & amortization000000000000
EBIT−20−20−23−25−16−5−3−32−25−32−40−59